Unjha Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-11-2024
- Paid Up Capital ₹ 0.45 M
as on 16-11-2024
- Company Age 24 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 Cr
as on 16-11-2024
- Revenue 2.00%
(FY 2023)
- Profit 3.56%
(FY 2023)
- Ebitda 9.45%
(FY 2023)
- Net Worth 10.29%
(FY 2023)
- Total Assets 12.04%
(FY 2023)
About Unjha Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.45 M.
The company currently has active open charges totaling ₹2.00 Cr.
Jashvant Shah, Shobhnaben Shah, Arpita Shah, and One other member serve as directors at the Company.
- CIN/LLPIN
U24134GJ2000PTC038943
- Company No.
038943
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Nov 2000
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Unjha Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jashvant Shah  | Director | 20-Nov-2000 | Current |
| Shobhnaben Shah | Director | 20-Nov-2000 | Current |
| Arpita Shah | Director | 24-Mar-2015 | Current |
| Malav Shah | Director | 24-Mar-2015 | Current |
Financial Performance of Unjha Pharmaceuticals.
Unjha Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2% increase. The company also saw a slight improvement in profitability, with a 3.56% increase in profit. The company's net worth Soared by an impressive increase of 10.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unjha Pharmaceuticals?
In 2023, Unjha Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Aura Nutraceuticals LimitedActive 23 years 2 months
Jashvant Shah, Shobhnaben Shah and 2 more are mutual person
- Unjha Life Science Private LimitedActive 10 years 6 days
Arpita Shah and Malav Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 04 Mar 2010 | ₹2.00 Cr | Open |
How Many Employees Work at Unjha Pharmaceuticals?
Unlock and access historical data on people associated with Unjha Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unjha Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unjha Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
